Document is current
Any future updates will be listed below
-
Authors
Herzog, Rubén https://orcid.org/0000-0002-3498-5819
Barbey, Florentine Marie
Islam, Md Nurul https://orcid.org/0000-0001-7905-7373
Rueda-Delgado, Laura https://orcid.org/0000-0002-8730-8977
Nolan, Hugh
Prado, Pavel https://orcid.org/0000-0002-1324-6400
Krylova, Marina https://orcid.org/0000-0001-7447-3976
Izyurov, Igor
Javaheripour, Nooshin
Danyeli, Lena Vera
Sen, Zümrüt Duygu
Walter, Martin https://orcid.org/0000-0001-7857-4483
O’Donnell, Patricio
Buhl, Derek L.
Murphy, Brian
Ibanez, Agustin https://orcid.org/0000-0001-6758-5101
- License Information
-
More Information
Article History
Received: 13 February 2024
Revised: 12 July 2024
Accepted: 17 July 2024
First Online: 27 July 2024
Competing interests
: FB, MI, HN, BM and LR-D are employees and shareholders of Cumulus Neuroscience Ltd. MW is a member of the following advisory boards and has given presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. DLB and PO were employees and shareholders of Takeda Pharmaceuticals at the time of the original study. The other authors declare that they have no competing interests.
